Related references
Note: Only part of the references are listed.Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease
Robert J. Baranello et al.
CURRENT ALZHEIMER RESEARCH (2015)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
Effects of Neutral Endopeptidase (Neprilysin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat
Jonathan R. Dalzell et al.
CARDIOVASCULAR THERAPEUTICS (2014)
Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Neprilysin Inhibition for Heart Failure REPLY
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes
J. Scott Miners et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s disease
Natalia N. Nalivaeva et al.
Frontiers in Aging Neuroscience (2014)
Time and Technology Will Tell The Pathophysiologic Basis of Neurohormonal Modulation in Heart Failure
Brent N. Reed et al.
HEART FAILURE CLINICS (2014)
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)
Sanae Hamaguchi et al.
JOURNAL OF CARDIOLOGY (2013)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Novel Protein Therapeutics for Systolic Heart Failure
Horng H. Chen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat
Laxminarayan G. Hegde et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
C. M. O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Renal effects of ularitide in patients with decompensated heart failure
Hartmut Luess et al.
AMERICAN HEART JOURNAL (2008)
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema
R. M. Fryer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial
Clyde W. Yancy et al.
CIRCULATION-HEART FAILURE (2008)
Combining neuroendocrine inhibitors in heart failure: Reflections on safety and efficacy
Hani Jneid et al.
AMERICAN JOURNAL OF MEDICINE (2007)
Bioenergetic protection of failing atrial and ventricular myocardium by vasopeptidase inhibitor omapatrilat
YM Cha et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: Results of a pilot study
M Packer et al.
JOURNAL OF CARDIAC FAILURE (2005)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure
NLM Cruden et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
Adrenomedullin (ADM) in the human forearm vascular bed:: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP)
IB Wilkinson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
JL Rouleau et al.
LANCET (2000)
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
DR McClean et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
